Pharmaceutical Executive-04-01-2017

For Bahija Jallal, chosen this year's Healthcare Businesswomen’s Association Woman of the Year, a passion for translational science has been the central guide in a career rise from cancer researcher to leading a big pharma biotech engine.

Pilot study affirms the value of a standards-based solution for prescription drug traceability-and the need to start now to meet compliance deadlines for the Drug Supply Chain Security Act.

A review of some of the sales strategy insights on offer at last month’s eyeforpharma Barcelona event.

Experts debate the practice’s rise up the life sciences agenda.

Two topics in Pharm Exec this month-rare disease research and women in healthcare leadership-share a "common" thread.

Six years in, Pharm Exec looks at the progress of the International Rare Diseases Research Consortium-an ambitious global effort focused on accelerating orphan disease diagnosis, and ultimately enabling better treatment options for these underserved patient populations.

It is hard to resist the sensation that the rhetoric of Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.

Jill Wechsler outlines how the new FDA commissioner tasked with curbing regulation, speeding approvals-and collecting more fees to do it.

A conversation with Tommy Fanning, head of biopharma at IDA Ireland, about the country’s growth as a manufacturing powerhouse-and its bid to attract UK-based EMA post-Brexit.

Click the title above to open the Pharmaceutical Executive April 2017 issue in an interactive PDF format.

Is the Greek pharmaceuticals and healthcare sector, once a strong bridge between Europe and the East, on the mend after suffering the recent ravages of the global financial crisis and subsequent austerity policies?